LuMend expands CTO (chronic total occlusions) catheter use in the US:
This article was originally published in Clinica
LuMend has received US clearance to expand the market for its catheter for crossing chronic total occlusions (CTOs) from use in the just coronary vessels to use in the peripheral vasculature. The Frontrunner CTO catheter, claimed to be the only device specifically approved for both types of vessels, features controlled, blunt micro-dissection that gently separates atherosclerotic plaque, creating a passage through the CTO. It can move through longer peripheral CTOs in a "more expeditious manner" than standard guidewire techniques, said the Redwood City, California firm.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.